This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/pubchem-compound/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n11http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/drugbank/
n24http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n25http://www.rxlist.com/cgi/generic/
n21http://linked.opendata.cz/resource/drugbank/patent/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/chemspider/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01332/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01332
rdf:type
n3:Drug
n3:description
A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. [PubChem]
n3:group
approved
n3:indication
For the treatment of infections due to susceptible strains of microorganisms.
owl:sameAs
n8:DB01332 n24:DB01332
dcterms:title
Ceftizoxime
adms:identifier
n10:5018818 n12:DB01332 n13:553473 n14:6533629 n15:C06890 n16:0469-7271-01 n17:46505647 n22:Ceftizoxime n23:PA164748758
n3:mechanismOfAction
Ceftizoxime is an aminothiazolyl cephalosporin with an extended spectrum of activity against many gram-negative, nosocomially acquired pathogens. It has excellent beta-lactamase stability, with good in vitro activity against Haemophilus influenzae, Neisseria gonorrhoeae and Klebsiella pneumoniae. Ceftizoxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that ceftizoxime interferes with an autolysin inhibitor.
n3:packager
n11:271B3F78-363D-11E5-9242-09173F13E4C5 n11:271B3F77-363D-11E5-9242-09173F13E4C5
n3:patent
n21:1321580
n3:routeOfElimination
Ceftizoxime is not metabolized, and is excreted virtually unchanged by the kidneys in 24 hours.
n3:synonym
CEFIZOX Ceftizoxima Syn-7-(2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid Ceftizoxime Ceftizoximum
n3:proteinBinding
30% protein bound
n3:synthesisReference
Norio Ohnishi, Rinta Ibuki, "Method for preparing stable crystals of salt of Ceftizoxime." U.S. Patent US4390694, issued October, 1981.
n26:hasConcept
n27:M0023550
foaf:page
n20:ceftizoxime.html n25:ceftizox.htm
n3:IUPAC-Name
n4:271B3F7D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F83-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F82-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F7F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F80-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F81-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F7B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F79-363D-11E5-9242-09173F13E4C5 n4:271B3F7C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F7A-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:J01DD07
n3:H-Bond-Acceptor-Count
n4:271B3F89-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F8A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F84-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F85-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F87-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F86-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F88-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
68401-81-0
n3:category
n3:Bioavailability
n4:271B3F8F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F91-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F92-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3F93-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F8E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F8D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F90-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F7E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F8B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F8C-363D-11E5-9242-09173F13E4C5